ADAP:NSD-Adaptimmune Therapeutics Plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.08

Change

+0.02 (+1.42)%

Market Cap

USD 0.17B

Volume

0.31M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


ADAP Stock Forecast & Price:
Based on the Adaptimmune Therapeutics Plc stock forecasts from 0 analysts, the average analyst target price for Adaptimmune Therapeutics Plc is not available over the next 12 months. Adaptimmune Therapeutics Plc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Adaptimmune Therapeutics Plc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Adaptimmune Therapeutics Plc’s stock price was USD 1.08. Adaptimmune Therapeutics Plc’s stock price has changed by -8.12% over the past week, -44.59% over the past month and -79.21% over the last year.

About Adaptimmune Therapeutics Plc (ADAP:NSD)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platfo ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

-2.95 (-0.43%)

USD76.14B 13.80 10.63
VRTX Vertex Pharmaceuticals Inc

-3.26 (-1.11%)

USD73.02B 23.28 15.15
MRNA Moderna Inc

+0.18 (+0.15%)

USD46.19B 3.66 2.45
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+1.28 (+0.96%)

USD30.98B 2.87 1.32
RPRX Royalty Pharma Plc

-0.15 (-0.37%)

USD27.19B 39.06 19.32
SGEN Seagen Inc

+1.13 (+0.83%)

USD25.40B 55.02 -36.47
ALNY Alnylam Pharmaceuticals Inc

-9.23 (-4.41%)

USD25.13B N/A -31.40
GMAB Genmab AS

+0.20 (+0.63%)

USD21.66B 41.88 3.47
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ADAP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -71.33% 23% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -71.33% 23% F 17% F
Trailing 12 Months  
Capital Gain -80.06% 24% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -80.06% 24% F 16% F
Trailing 5 Years  
Capital Gain -86.87% 31% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -86.87% 31% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain 24.35% 80% B- 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.35% 80% B- 82% B-
Risk Return Profile  
Volatility (Standard Deviation) 155.55% 10% F 7% F
Risk Adjusted Return 15.65% 71% C- 53% F
Market Capitalization 0.17B 56% F 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.38 59% F 51% F
Price / Cash Flow Ratio 16.29 4% F 15% F
EV/EBITDA 0.22 28% F 47% F
Management Effectiveness  
Return on Equity -83.86% 35% F 19% F
Return on Invested Capital -59.01% 44% F 22% F
Return on Assets -28.72% 46% F 17% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 13.98 13% F 6% F
Short Percent 2.63% 58% F 47% F
Beta 1.75 20% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector